Autoimmune Neutropenia
4
2
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
11 treatments under study, led by Cytokine Essays
Research Leaders
5 sponsors active, led by Children's Hospital of Philadelphia
Related Conditions
Often studied with 15 related conditions
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders
Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune Cytopenia
Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
Sirolimus for Autoimmune Disease of Blood Cells
Research Network
Common Treatments
- Cytokine Essays1
- Thrombopoietin Receptor Agonist1
- Granulocyte Colonystimulating Factor1
- Mavorixafor1
- Blood Sample1
Active Sponsors
- Children's Hospital of Philadelphia1
- University Hospital, Bordeaux1
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico1
- Ministry for Health and Solidarity, France1
- X4 Pharmaceuticals1
Top Investigators
University Hospital, Bordeaux
Children's Hospital of Philadelphia
Related Conditions
- Autoimmune Hemolytic Anemia2
- Chronic Idiopathic Neutropenia2
- Immune Thrombocytopenia2
- Idiopathic Thrombocytopenic Purpura1
- Autoimmune Lymphoproliferative Syndrome Alps1